[go: up one dir, main page]

WO2008131163A8 - Enzymatic anticancer therapy - Google Patents

Enzymatic anticancer therapy Download PDF

Info

Publication number
WO2008131163A8
WO2008131163A8 PCT/US2008/060733 US2008060733W WO2008131163A8 WO 2008131163 A8 WO2008131163 A8 WO 2008131163A8 US 2008060733 W US2008060733 W US 2008060733W WO 2008131163 A8 WO2008131163 A8 WO 2008131163A8
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer therapy
enzymatic
enzymatic anticancer
patient
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/060733
Other languages
French (fr)
Other versions
WO2008131163A1 (en
Inventor
David R. Filpula
Puja Sapra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08754910.1A priority Critical patent/EP2147122B1/en
Priority to BRPI0810384A priority patent/BRPI0810384B8/en
Priority to JP2010504262A priority patent/JP5595904B2/en
Priority to ES08754910.1T priority patent/ES2507508T3/en
Priority to DK08754910.1T priority patent/DK2147122T3/en
Priority to SI200831301T priority patent/SI2147122T1/en
Priority to CA2684749A priority patent/CA2684749C/en
Priority to CN200880021105.8A priority patent/CN101680039B/en
Priority to NZ580980A priority patent/NZ580980A/en
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Priority to AU2008242791A priority patent/AU2008242791B2/en
Priority to HRP20140947AT priority patent/HRP20140947T1/en
Priority to PL08754910T priority patent/PL2147122T3/en
Priority to MX2009011320A priority patent/MX2009011320A/en
Publication of WO2008131163A1 publication Critical patent/WO2008131163A1/en
Priority to IL201593A priority patent/IL201593A/en
Anticipated expiration legal-status Critical
Publication of WO2008131163A8 publication Critical patent/WO2008131163A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

What is provided is a method of treating a patient having a tumor comprising administering an effective amount of adenosine deaminase, preferably polyalkylene oxide conjugated, to a patient in need thereof.
PCT/US2008/060733 2007-04-20 2008-04-18 Enzymatic anticancer therapy Ceased WO2008131163A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
NZ580980A NZ580980A (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
JP2010504262A JP5595904B2 (en) 2007-04-20 2008-04-18 Anticancer treatment with enzymes
AU2008242791A AU2008242791B2 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
DK08754910.1T DK2147122T3 (en) 2007-04-20 2008-04-18 ENZYMATIC CANCER TREATMENT
SI200831301T SI2147122T1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
CA2684749A CA2684749C (en) 2007-04-20 2008-04-18 Use of adenosine deaminase for cancer therapy
CN200880021105.8A CN101680039B (en) 2007-04-20 2008-04-18 Enzyme Anticancer Therapy
EP08754910.1A EP2147122B1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
ES08754910.1T ES2507508T3 (en) 2007-04-20 2008-04-18 Enzymatic anti-cancer therapy
BRPI0810384A BRPI0810384B8 (en) 2007-04-20 2008-04-18 anticancer enzyme therapy
HRP20140947AT HRP20140947T1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
PL08754910T PL2147122T3 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
MX2009011320A MX2009011320A (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy.
IL201593A IL201593A (en) 2007-04-20 2009-10-18 Compositions comprising adenosine deaminase for use in treating tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91303907P 2007-04-20 2007-04-20
US60/913,039 2007-04-20

Publications (2)

Publication Number Publication Date
WO2008131163A1 WO2008131163A1 (en) 2008-10-30
WO2008131163A8 true WO2008131163A8 (en) 2010-01-28

Family

ID=39875909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/060733 Ceased WO2008131163A1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy

Country Status (19)

Country Link
US (1) US8741283B2 (en)
EP (1) EP2147122B1 (en)
JP (1) JP5595904B2 (en)
KR (1) KR101540296B1 (en)
CN (1) CN101680039B (en)
BR (1) BRPI0810384B8 (en)
CA (1) CA2684749C (en)
CY (1) CY1117000T1 (en)
DK (1) DK2147122T3 (en)
ES (1) ES2507508T3 (en)
HR (1) HRP20140947T1 (en)
IL (1) IL201593A (en)
MX (1) MX2009011320A (en)
NZ (1) NZ580980A (en)
PL (1) PL2147122T3 (en)
PT (1) PT2147122E (en)
SI (1) SI2147122T1 (en)
TW (1) TWI486169B (en)
WO (1) WO2008131163A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857880A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
CN101688244B (en) 2007-04-20 2013-05-08 希格马托罕见疾病公司 Stable recombinant adenosine deaminase
CA2825981A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
WO2016061286A2 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016191283A2 (en) * 2015-05-22 2016-12-01 University Of Houston System Enzymatic immunomodulation of solid tumors and user thereof
US20190343935A1 (en) * 2016-03-11 2019-11-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
JP2020516654A (en) 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド Combination cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
SG11202103317XA (en) 2018-10-17 2021-05-28 Senti Biosciences Inc Combinatorial cancer immunotherapy
US20250075196A1 (en) * 2021-11-12 2025-03-06 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same
US20240250753A1 (en) * 2022-10-10 2024-07-25 Berkeley Marine Robotics Inc. Ship Hull Inspection using a Swarm of Unmanned Underwater Vehicles equipped with Wireless Laser Systems

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346823A (en) 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6251382B1 (en) 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6824766B2 (en) 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US20020088017A1 (en) 1999-04-28 2002-07-04 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6579857B1 (en) 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
AU7868400A (en) * 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
US20030009017A1 (en) * 2000-11-08 2003-01-09 Leiby Kevin R. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
AU2002365360A1 (en) * 2001-11-28 2003-06-10 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
CA2470104C (en) * 2001-12-12 2015-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7413738B2 (en) 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
US7301003B2 (en) 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
WO2007149686A2 (en) 2006-06-21 2007-12-27 Enzon Pharmaceuticals, Inc. Stabilized proteins
KR20090083334A (en) 2006-09-15 2009-08-03 엔존 파마슈티컬즈, 인코포레이티드 Polyalkylene oxides with hindered ester based biodegradable linkers
TW200835514A (en) 2006-12-29 2008-09-01 Enzon Pharmaceuticals Inc Use of adenosine deaminase for treating pulmonary disease
CN101688244B (en) 2007-04-20 2013-05-08 希格马托罕见疾病公司 Stable recombinant adenosine deaminase

Also Published As

Publication number Publication date
CA2684749C (en) 2016-06-21
CA2684749A1 (en) 2008-10-30
WO2008131163A1 (en) 2008-10-30
ES2507508T3 (en) 2014-10-15
EP2147122A1 (en) 2010-01-27
BRPI0810384B8 (en) 2021-05-25
AU2008242791A1 (en) 2008-10-30
JP2010524968A (en) 2010-07-22
NZ580980A (en) 2012-04-27
JP5595904B2 (en) 2014-09-24
KR20090130108A (en) 2009-12-17
HRP20140947T1 (en) 2015-02-13
IL201593A (en) 2017-07-31
DK2147122T3 (en) 2014-10-13
CN101680039A (en) 2010-03-24
MX2009011320A (en) 2009-12-15
BRPI0810384A2 (en) 2014-11-04
RU2009142817A (en) 2011-05-27
TWI486169B (en) 2015-06-01
PT2147122E (en) 2014-10-15
PL2147122T3 (en) 2015-05-29
SI2147122T1 (en) 2015-01-30
TW200902051A (en) 2009-01-16
KR101540296B1 (en) 2015-07-31
US20090047270A1 (en) 2009-02-19
BRPI0810384B1 (en) 2021-02-02
US8741283B2 (en) 2014-06-03
CN101680039B (en) 2016-08-24
EP2147122B1 (en) 2014-07-16
EP2147122A4 (en) 2010-11-17
CY1117000T1 (en) 2017-04-05
IL201593A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
WO2008131163A8 (en) Enzymatic anticancer therapy
WO2008054585A3 (en) Use of pegylated il-10 to treat cancer
WO2012002760A3 (en) Method for treating and diagnosing cancer by using cell-derived microvesicles
WO2008091375A3 (en) Attenuated salmonella as a delivery system for sirna-based tumor therapy
WO2012045090A3 (en) Therapeutic use of a tlr agonist and combination therapy
WO2007089945A3 (en) Treating diseases by targeting silt3
WO2009134866A3 (en) Cell membrane engineering
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
WO2008132234A3 (en) Rna antagonist compounds for the modulation of beta-catenin
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2012138694A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2009095261A3 (en) Vaccine compositions
HK1197276A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2011109422A8 (en) Compositions and methods for the treatment of cancer
WO2008118785A3 (en) Methods for treating depression using immediate-impact treatments and d-cycloserine
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2008039994A3 (en) Targeted photodynamic therapy agent
WO2010019717A3 (en) Combination therapy of hiv fusion/entry inhibitors targeting gp41
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
GEP20125689B (en) New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkylsulfonamide derivatives of epipodophyllotoxin, preparation process thereof, and application thereat therapy as anticancer agents
WO2008024844A3 (en) Anticancer combination therapies
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021105.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754910

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1927/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 201593

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2684749

Country of ref document: CA

Ref document number: 2010504262

Country of ref document: JP

Ref document number: MX/A/2009/011320

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008242791

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 580980

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 20097023239

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008754910

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009142817

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008242791

Country of ref document: AU

Date of ref document: 20080418

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0810384

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091020